RADIOPHARMACEUTICAL TREATMENTS AND HTA: THE CASE OF [177LU]-DOTATATE

被引：0
|
作者：
Garagiola, E. [1 ]
Ferrario, L. B. [1 ]
Bagni, O. [2 ]
Grana, C. M. [3 ]
Lastoria, S. [4 ]
Pellerito, R. E. [5 ]
Salgarello, M. [6 ]
Seregni, E. [7 ]
Severi, S. [8 ]
Storto, G. [9 ]
Versari, A. [10 ]
Foglia, E. [1 ]
机构：
[1] LIUC Univ, Castellanza, Italy
[2] ASL Santa Maria Goretti Hosp, Latina, Italy
[3] IEO European Inst Oncol, Milan, Italy
[4] Sci Inst Res Hospitalizat & Healthcare Pascale Fd, Canc Natl Inst, Naples, Italy
[5] Ordine Mauriziano Hosp, Turin, Italy
[6] Sacro Cuore Don Calabria Hosp, Sci Inst Res Hospitalizat & Healthcare, Negrar Di Valpolicella, Italy
[7] Sci Inst Res Hospitalizat & Healthcare Fdn, Canc Natl Inst, Milan, Italy
[8] IRCCS Ist Romagnolo Tumori Dino Amadori IRST, Meldola, Italy
[9] Sci Inst Res Hospitalizat & Healthcare, Referral Canc Ctr Basilicata, Rionero In Vulture, Italy
[10] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC257
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [1] 177Lu-DOTATATE: comparative study between 177Lu NRG/Netherlands and 177Lu ORNL/USA
    Caldeira Filho, Jose de Souza
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 691 - 692
  • [2] Requirements on specific activity (SA) of 177Lu to radiolabel DOTATATE for PRRT: studies on labeling 0.2 mg DOTATATE with 7.4 GBq 177Lu at several SA of 177Lu
    Breeman, W. A. P.
    de Blois, E.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [3] Preparation of Patient Doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) 177Lu
    Nanabala, Raviteja
    Pillai, Maroor Raghavan Ambikalmajan
    Gopal, Buvaneswari
    [J]. NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 56 (06) : 313 - 322
  • [4] 177Lu Dotatate vs. Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit
    Page, E.
    Tipping, J.
    Birch, E.
    Hamilton, D.
    Manoharan, P.
    [J]. NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 137 - 138
  • [5] Preparation of Patient Doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) 177Lu
    Raviteja Nanabala
    Maroor Raghavan Ambikalmajan Pillai
    Buvaneswari Gopal
    [J]. Nuclear Medicine and Molecular Imaging, 2022, 56 : 313 - 322
  • [6] Extravasation After [177Lu]Lu-HA-DOTATATE Therapy
    de Vries-Huizing, Daphne M. V.
    Cheung, Zing J.
    Hendrikx, Jeroen J. M. A.
    Donswijk, Maarten L.
    Versleijen, Michelle W. J.
    [J]. CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) : 454 - 456
  • [7] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [8] Thymoma Treated With 177Lu DOTATATE Induction and Maintenance PRRT
    Makis, William
    McCann, Karey
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (05) : E278 - E281
  • [9] Radiation Safety Observations Associated with 177Lu Dotatate Patients
    Nelson, Kevin L.
    Sheetz, Michael A.
    [J]. HEALTH PHYSICS, 2019, 117 (06): : 680 - 687
  • [10] Rhabdoid Papillary Meningioma Treated With 177Lu DOTATATE PRRT
    Makis, William
    McCann, Karey
    McEwan, Alexander J. B.
    [J]. CLINICAL NUCLEAR MEDICINE, 2015, 40 (03) : 237 - 240
12345